MedTrace Logo

Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis

NCT05857514 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2023-06-28

No results posted yet for this study

Summary

The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis. The main question it aims to answer is: whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis Participants will be patients who give consent to the study and who are required to undergo ERCP as part of their standard care.

If there is a comparison group: Researchers will compare \[rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.\] to see if \[whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis\].

Conditions

  • Post-ERCP Acute Pancreatitis

Interventions

DRUG

Rectal Indomethacin

Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis

PROCEDURE

Prophylactic Pancreatic duct stenting

Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis

Sponsors & Collaborators

  • Moti Lal Nehru Medical College

    lead OTHER_GOV

Principal Investigators

  • Mukti Pr Meher, MBBS, MD · Investigator

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05857514 on ClinicalTrials.gov